Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q2 2026
Institutional positions in Aligos Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 31
- −4 vs. Q1 2026
- Shares held
- 2.29M
- −482.6K (−17.4%) vs. Q1 2026
- Total value
- $13.2M
- −$7.39M (−35.8%) vs. Q1 2026
- New holders
- 5
- 7 more added
- Sold out
- 9
- 7 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALGS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.2M |
| Q1 2026 | 35 | $20.6M |
| Q4 2025 | 41 | $26.2M |
| Q3 2025 | 33 | $26.0M |
| Q2 2025 | 37 | $19.5M |
| Q1 2025 | 35 | $27.1M |
| Q4 2024 | 34 | $64.5M |
| Q3 2024 | 27 | $14.7M |
| Q2 2024 | 49 | $16.6M |
| Q1 2024 | 49 | $45.3M |
| Q4 2023 | 40 | $30.1M |
| Q3 2023 | 36 | $19.2M |
| Q2 2023 | 41 | $25.5M |
| Q1 2023 | 46 | $23.9M |
| Q4 2022 | 39 | $25.3M |
| Q3 2022 | 52 | $30.4M |
| Q2 2022 | 60 | $36.0M |
| Q1 2022 | 76 | $68.4M |
| Q4 2021 | 71 | $390.4M |
| Q3 2021 | 68 | $483.9M |
| Q2 2021 | 58 | $550.5M |
| Q1 2021 | 52 | $612.4M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Aligos Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 444,110 | $2.56M | 0.04% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 412,000 | $2.38M | 0.01% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 327,237 | $1.89M | 0.32% | 00.0% | Unchanged |
| Marshall Wace, LLP | 246,579 | $1.42M | 0.00% | −20,556−7.7% | Reduced |
| Woodline Partners LP | 177,362 | $1.02M | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 175,543 | $1.01M | 0.00% | −2,719−1.5% | Reduced |
| Baker Bros. Advisors LP | 83,055 | $479.2K | 0.00% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 76,247 | $439.9K | 0.05% | 00.0% | Unchanged |
| D. E. Shaw & Co., Inc. | 66,463 | $383.5K | 0.00% | +55,485+505.4% | Added |
| UBS Group AG | 59,986 | $346.1K | 0.00% | +22,925+61.9% | Added |
| Geode Capital Management, LLC | 47,173 | $272.3K | 0.00% | −2,802−5.6% | Reduced |
| Jane Street Group, LLC | 32,402 | $187.0K | 0.00% | +32,402 | New |
| BlackRock, Inc. | 30,292 | $174.8K | 0.00% | +17,252+132.3% | Added |
| Vanguard Fiduciary Trust Co | 28,612 | $165.1K | 0.00% | +175+0.6% | Added |
| Dimensional Fund Advisors LP | 21,044 | $121.4K | 0.00% | +21,044 | New |
| Verition Fund Management LLC | 18,887 | $109.0K | 0.00% | 00.0% | Unchanged |
| Trexquant Investment LP | 12,339 | $71.2K | 0.00% | +12,339 | New |
| Renaissance Technologies LLC | 10,800 | $62.3K | 0.00% | −89,650−89.2% | Reduced |
| Rockefeller Capital Management L.P. | 10,000 | $57.7K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 4,650 | $26.8K | 0.00% | +3,700+389.5% | Added |
| Golden State Wealth Management, LLC | 2,674 | $15.4K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 2,125 | $12.0K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 1,808 | $10.4K | 0.00% | +1,808 | New |
| Tower Research Capital LLC (TRC) | 359 | $2.07K | 0.00% | +294+452.3% | Added |
| JPMorgan Chase & Co | 344 | $1.87K | 0.00% | −330−49.0% | Reduced |
| Morgan Stanley | 204 | $1.18K | 0.00% | −14−6.4% | Reduced |
| SBI Securities Co., Ltd. | 126 | $727 | 0.00% | +100+384.6% | Added |
| Wells Fargo & Company | 100 | $577 | 0.00% | −600−85.7% | Reduced |
| FMR LLC | 10 | $58 | 0.00% | +10 | New |
| ZRC Wealth Management, LLC | 4 | $24 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 3 | $17 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 0 | $0 | 0.00% | −229,754−100.0% | Sold out |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −148,799−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −54,311−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −51,500−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −23,093−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −14,196−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −10,822−100.0% | Sold out |
| Vanguard Global Advisers, LLC | 0 | $0 | 0.00% | −936−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −68−100.0% | Sold out |